"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance

Author's Avatar
Jan 28, 2023

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today presented interim data from its Phase II clinical study evaluating an "extra-strength" formulation for extended duration of Jeuveau® (prabotulinumtoxinA-xvfs), its flagship neurotoxin product, at the 2023 International Master Course on Aging Science (IMCAS) World Congress in Paris. The data indicated that the “extra-strength” formulation of Jeuveau® at 40U (units) achieved a duration profile of 6 months or 26 weeks.